AUTHORS
Taylor R. Brooks, MD, Emma Williams, MD, PhD2, Priyanka A. Pophali, MD3, Stephanie Franco, MD4, Natalie S Grover, MD5, Adrienne N. Nedved, PharmD, MPA6, Yucai Wang, MD, PhD7, Tenley Schwarz8, Matthew Schwede, MD, MS9, Saloni Savani, MD10, Cyrus Khan, MD11, Sally Jones, MD12, Aditi Saha, MD13, Paolo Fabrizio Caimi, MD14, Brian Hill, MD, PhD15
AFFILIATIONS
1 Cleveland Clinic, Cleveland, Ohio, United States
2 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
3 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
4 University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
5 University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Swedish Cancer Institute, Seattle, Washington, United States
9 Swedish Cancer Institute, Seattle, Washington, United States
10 Allegheny Health Network, Pittsburgh, Pennsylvania, United States
11 UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
12 University of Alabama, Birmingham, Birmingham, Alabama, United States
13 University of Alabama, Birmingham, Birmingham, Alabama, United States
14 Cleveland Clinic, Cleveland, Ohio, United States
15 Cleveland Clinic, Cleveland, Ohio, United States
ABSTRACT
Introduction: Relapsed or refractory (r/r) mantle cell lymphoma (MCL) progressing after treatment with covalent Bruton’s tyrosine kinase inhibitor (BTKi) and/or CD19 chimeric antigen receptor (CAR) T-cell therapy has a poor prognosis and no standard of care. CD20×CD3 bispecific antibodies (BsAbs) are active in early-phase MCL studies and often used off label based on national guidelines, but real-world data are limited. We report bispecific antibody treatment outcomes for r/r MCL across the multicenter REALBiTE consortium.
Methods: We retrospectively analyzed adults with r/r MCL who received BsAb therapy between 2023 and 2026 at 7 academic centers in the United States. Baseline characteristics, including secondary MIPI, morphology, Ki-67, and TP53 status were assessed at BsAb initiation. Responses were investigator-assessed per Lugano criteria and CRS/ICANS were graded per consensus criteria. Overall survival (OS), progression-free survival (PFS), and duration of response (DoR) were estimated by the Kaplan-Meier method from the first BsAb dose. The cumulative incidence of relapse versus non-relapse mortality (NRM) was estimated with a competing-risks (Aalen-Johansen) model. Exact (Clopper-Pearson) 95% confidence intervals (CIs) are reported where indicated.
Results: Sixteen eligible patients were analyzed. Median age was 72 years (range 42-86), 11 (69%) were male. The population was enriched for individuals with high-risk disease characteristics: Ann Arbor stage IV in 15 (94%), ECOG performance status ≥2 in 4 (25%), bulky disease in 2 (12%), Ki-67 >30% in 11 (69%), high-risk (i.e., ≥6.2) MIPI at the time of BsAb treatment in 10 (62%), blastoid or pleomorphic morphology in 5 (31%), and TP53 aberration in 4 (25%). Two patients (13%) had central nervous system (CNS) involvement by MCL, with one having active CNS disease at the time of BsAb initiation. Patients were heavily pretreated, with a median of 4 prior lines (range 2-7). Thirteen (81%) had progressed on a covalent BTKi, and 7 (44%) following prior CD19 CAR T therapy (n=6 brexu-cel, n=1 axi-cel, 1/7 progressed within 90 days of cellular infusion). A total of 7 (44%) were refractory to the line of therapy immediately preceding BsAb. Most patients (14/16, 88%) received glofitamab and the remaining 2/16 (12%) received mosunetuzumab monotherapy. Patients received a median of 5 full doses of BsAb, with 6 (38%) completing all planned doses of therapy. Among 13 evaluable patients, ORR was 85% (95% CI 55-98%) and CR rate was 69% (39-91%); median time to best response was 86 days. At a median follow-up of 13.9 months, median PFS and OS were both 20.0 months, with 6-month OS and PFS of 73% and 60%, respectively. Median DoR was 17.2 months (6-month DoR 89%). The cumulative incidence of relapse was 27% at both 6 and 12 months, and 12-month NRM was 13%; two deaths were attributed to CRS and one death due to secondary malignancy. One individual experienced grade 4 CRS on day 8 of glofitamab therapy, and died of CRS on day 8. A second individual experienced grade 2 CRS on day 8 of glofitamab and grade 2 ICANS on day 12, which worsened until death on day 16. Any-grade CRS occurred in 11 (69%). Of these, the majority were grade 1-2 (9/11, 82%). Median time to max grade CRS was 1 day. Any-grade ICANS occurred in 3 patients (19%), all grade 1. Tocilizumab was administered in 10 patients (62%) and rescue corticosteroids in 8 (50%). Three patients (19%) proceeded to subsequent CD19 CAR T (n=2 liso-cel, n=1 brexu-cel) as consolidation of a response to BsAb therapy, one patient in CR, one in PR, and one not evaluable prior to CAR T. The ORR to subsequent CAR T was 100% (all CR); all 3 experienced CRS to subsequent CAR T, all of which were grade 1.
Conclusions: In this real-world, high-risk r/r MCL cohort enriched for patients with BTKi refractoriness and high-risk features, CD20×CD3 BsAbs (mostly glofitamab) produced a high response rate. CRS was predominantly low grade and no severe ICANS occurred; however, fatal CRS events underscore the need for vigilance during step-up dosing. Although follow-up remains short, responses were durable in a subset. Some patients proceeded to subsequent CAR T, supporting BsAbs as a bridge to cellular therapy in select cases. These findings demonstrate real-world efficacy and safety of BsAbs and support additional prospective evaluation of these agents for use in patients with r/r MCL, both as monotherapy and in combination with other active agents.
DISCLOSURES
Taylor R. Brooks, MD: No relevant conflicts of interest to declare.